Asset Details
Do you wish to reserve the book?
From silent partners to potential therapeutic targets: macrophages in colorectal cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
From silent partners to potential therapeutic targets: macrophages in colorectal cancer
Do you wish to request the book?
From silent partners to potential therapeutic targets: macrophages in colorectal cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
From silent partners to potential therapeutic targets: macrophages in colorectal cancer
2025
Overview
Cancer cells grow and survive in the tumor microenvironment, which is a complicated process. As a key part of how colorectal cancer (CRC) progresses, tumor-associated macrophages (TAMs) exhibit a double role. Through angiogenesis, this TAM can promote the growth of cancers. Although being able to modify and adjust immune cells is a great advantage, these cells can also exhibit anti-cancer properties including direct killing of cancer cells, presenting antigens, and aiding T cell-mediated responses. The delicate regulatory mechanisms between the immune system and tumors are composed of a complex network of pathways regulated by several factors including hypoxia, metabolic reprogramming, cytokine/chemokine signaling, and cell interactions. Decoding and figuring out these complex systems become significant in building targeted treatment programs. Targeting TAMs in CRC involves disrupting chemokine signaling or adhesion molecules, reprogramming them to an anti-tumor phenotype using TLR agonists, CD40 agonists, or metabolic modulation, and selectively removing TAM subsets that promote tumor growth. Multi-drug resistance, the absence of an accurate biomarker, and drug non-specificity are also major problems. Combining macrophage-targeted therapies with chemotherapy and immunotherapy may revolutionize treatment. Macrophage studies will advance with new technology and multi-omics methodologies to help us understand CRC and build specific and efficient treatments.
Publisher
Springer Berlin Heidelberg,Springer Nature B.V,Springer
Subject
/ Animals
/ Cancer
/ Colorectal Neoplasms - drug therapy
/ Colorectal Neoplasms - immunology
/ Colorectal Neoplasms - pathology
/ Colorectal Neoplasms - therapy
/ Humans
/ Hypoxia
/ Medicine
/ Oncology
/ Review
/ Therapy
/ Tumor Microenvironment - immunology
/ Tumor-associated macrophages
/ Tumor-Associated Macrophages - drug effects
/ Tumor-Associated Macrophages - immunology
/ Tumor-Associated Macrophages - metabolism
/ Tumors
We currently cannot retrieve any items related to this title. Kindly check back at a later time.